Costly Registration Requirement Discouraging Trials in Russia

International Pharmaceutical Regulatory Monitor
A A
Mandatory local clinical trials required to register both novel and generic drugs in Russia are largely to blame for a decline in clinical trials there, according to a recent report by the Russia-based Association of Clinical Trials Organizations (ACTO).

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00